---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-25-000013"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:08:31.338447+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics Q1 net loss $18.1M; cash $92M; WTX-124 data/FDA in H2 2025

## Summary
- Net loss of $18.1M in Q1 2025 vs $16.2M in Q1 2024; R&D spend $13.1M.
- Cash and equivalents $92.0M as of March 31, 2025; runway into Q4 2026.
- WTX-124 Phase 1/1b on track for interim data and FDA regulatory discussions in H2 2025.
- First patient dosed in WTX-330 Phase 1b/2 trial; initial Phase 1 data showed clinical activity and tolerability.
- INDUCER T cell engager development candidate expected by end of Q2 2025; PREDATOR masking shown to silence peripheral activity.

## SEC filing metadata
- accession: 0001785530-25-000013
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553025000013/0001785530-25-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553025000013/howl-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-25-000013
- JSON: https://secwatch.observer/filing/0001785530-25-000013.json
- Plain text: https://secwatch.observer/filing/0001785530-25-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.